Duey Marc, a director at Aprea Therapeutics, Inc. (NASDAQ:APRE), recently acquired 30,000 shares of the company's common stock. The shares were purchased at a price of $4.39 each, amounting to a total transaction value of $131,700. Following this acquisition, Marc now directly owns 240,113 shares of Aprea Therapeutics. Additionally, Marc's spouse holds 602 shares indirectly, though Marc disclaims beneficial ownership of these securities.
InvestingPro Insights
The recent insider purchase by Director Duey Marc aligns with several key insights from InvestingPro. According to InvestingPro Tips, Aprea Therapeutics holds more cash than debt on its balance sheet, which could be seen as a positive sign for potential investors. This financial stability might have influenced Marc's decision to increase his stake in the company.
However, it's worth noting that Aprea is quickly burning through cash, as indicated by another InvestingPro Tip. This rapid cash burn rate could explain why the company's stock has experienced significant volatility, with a strong return over the last week and month, but a negative year-to-date performance of -25.53%.
The company's market capitalization stands at $19.01 million, reflecting its current valuation. Interestingly, the Price to Book ratio is 0.74, suggesting that the stock might be undervalued relative to its book value. This could potentially be another factor behind Marc's decision to increase his holdings.
It's important to note that Aprea Therapeutics is not currently profitable, with a negative gross profit margin of -552.7% for the last twelve months. Despite this, the company has shown impressive revenue growth of 410.91% over the same period, indicating potential for future development.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights. There are 10 more InvestingPro Tips available for Aprea Therapeutics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.